https://www.kangbixing.com/tumour/197572.html
拉罗替尼(Vitrakvi/Larotrectinib)为携带该罕见突变的患者提供了靶向治疗选项【康必行海外医疗】
拉罗替尼 作为全球首个获批的不分癌种、仅基于特定生物标志物(NTRK基因融合)的“广谱”高选择性原肌球蛋白受体激酶(TRK)抑制剂,其临床实践标志着“组织不可知论”精准治疗时代的实质性开端,为携带该罕见突变的患者提供了超越传统化疗及癌种特异性治疗的
vitrakvilarotrectinib
https://www.cdxtests.com/approval-context/vitrakvi-astrocytoma-and-oligodendroglioma
VITRAKVI for Astrocytoma and Oligodendroglioma | CDxTests.com | CDx Tests
FDA approval context for VITRAKVI in Astrocytoma and Oligodendroglioma. View biomarker requirements, eligible tests, and ordering options.
vitrakviastrocytomaoligodendrogliomacdxtests
https://www.medicines.org.uk/emc/product/12100/pil
VITRAKVI 25mg hard capsules - Patient Information Leaflet (PIL) - (emc) | 12100
VITRAKVI 25mg hard capsules - Patient Information Leaflet (PIL) by Bayer plc
patient information leafletvitrakvihardcapsulespil
https://www.chemdiv.com/company/media/pharma-news/2020/nice-backs-nhs-use-of-bayers-vitrakvi-via-the-cdf/
NICE backs NHS use of Bayer's Vitrakvi via the CDF - Chemdiv
NICE backs NHS use of Bayer's Vitrakvi via the CDF
nicebacksnhsusebayer
https://pharmacafennica.fi/spc/104722178
VITRAKVI oral lösning 20 mg/ml - Pharmaca Fennica
Pharmaca Fennica on terveydenhuollon ammattilaisten käyttämä lääketietopalvelu. Sovellus on tarkoitettu lääkkeen määräämiseen ja toimittamiseen oikeutetuille...
vitrakvioralpharmacafennica